Market Overview

Antares Pharma Given 5-Star Upgrade By Vetr

Share:

The Vetr community has upgraded Antares Pharma Inc. (NASDAQ: ATRS) from 4 stars to 5 stars.

The stock has traded up a little under $1 year-to-date with its second-quarter earnings report coming up on August 8.

See how crowdsourced ratings can help predict the market?

Vetr members have given Antares Pharma a Strong Buy rating and a $3.18 price target. This price target is higher than the $3.10 price target from professional analysts. The stock opened Wednesday around $3.18.

Of all Vetr voters, 100 percent believe traders should buy Antares stock while none believe that traders should sell Antares stock.

For Vetr’s full analysis of Antares, go here.

 

Related Articles (ATRS)

View Comments and Join the Discussion!

Posted-In: VetrUpgrades Crowdsourcing Analyst Ratings General

Latest Ratings

StockFirmActionPT
BIIBRBC CapitalMaintains277.0
RLICompass PointInitiates Coverage On90.0
CSCOWolfe ResearchDowngrades42.0
NKEBarclaysMaintains132.0
GILDRBC CapitalMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com